Top Markets
Coin of the day
Valerio Therapeutics S.A. Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO
Rang in Aktien #14050
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A.... Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Aktienkurs
$0.88012714
Zuletzt synchronisiert: 2026-08-31
Marktkapitalisierung
$439.58M
Veränderung (1 Tag)
-4.01%
Veränderung (1 Jahr)
1,131.97%
Land
FR
Handel Valerio Therapeutics S.A. (ALVIO)

Kategorie

Kursverlauf für Valerio Therapeutics S.A. (ALVIO)
Höchster Schlusskurs: $0.91 am 2026-08-01

Niedrigster Schlusskurs: $0.28 am 2023-06-01
Kursverlauf der Aktie von Valerio Therapeutics S.A. von 2023 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 53.06%
2025 116.87%
2024 -58.47%
2023 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$544.38 39.22%
US
$1.03K 45.21%
NL
$122.88 -10.84%
AU
$138.80 476.17%
US
$749.90 5.10%
CH